...
首页> 外文期刊>Infectious Diseases and Therapy >Stable Susceptibility to Aminoglycosides in an Age of Low Level, Institutional Use
【24h】

Stable Susceptibility to Aminoglycosides in an Age of Low Level, Institutional Use

机译:在低水平,机构使用的年龄对氨基糖苷的稳定敏感性

获取原文

摘要

Introduction The use of aminoglycosides has decreased dramatically over several decades in the United States due to the introduction of safer Gram-negative agents. This study was conducted to assess possibly changing aminoglycoside susceptibility rates between 2006 and 2012 and in reference to 1992 use in the context of aminoglycoside use volume. Methods Quarterly adult use of amikacin, gentamicin and tobramycin were determined from the Medical University of South Carolina Medical Center, Charleston, South Carolina, USA, pharmacy drug use database and expressed as total aminoglycoside defined daily doses per 1,000 patient days for the years 1992 and 2006 through 2012. Annual susceptibility of Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae, for the years 1992, 2006, and 2008 through 2012 were retrieved from our hospital’s clinical microbiology database (duplicate isolates were excluded). Quarterly and annualized aminoglycoside usage rates were compared to the other years of interest. Likewise, susceptibility rates of the target organisms to each aminoglycoside were also compared across the same timeframe. Results While total use of aminoglycosides decreased slightly from 1992 to 2006, it increased by about 40% between 2006 and 2008 and then stabilized. Changes in susceptibility rates between 1992 and 2006 were all ≤±9% with the exception of K. pneumoniae susceptibility to amikacin (?17%). Changes in susceptibility from 1992 to 2012 were also all ≤±9%. Tobramycin remained the most active versus P. aeruginosa (% susceptible?=?90), while amikacin remained most active versus E. coli and K. pneumoniae (% susceptible?=?98 and 98, respectively). Conclusion With low level use of aminoglycosides in our institution over the past 2 decades, the susceptibility of key Gram-negative pathogens has remained relatively stable, preserving these agents as potential alternative therapies as resistance arises to other frequently used antibiotics.
机译:简介在美国,由于引入了更安全的革兰氏阴性药物,氨基糖苷的使用已在数十年间急剧减少。进行这项研究的目的是评估2006年至2012年之间氨基糖苷敏感性的变化情况,并参考1992年氨基糖苷使用量的使用情况。方法从美国南卡罗来纳州查尔斯顿医科大学南卡罗来纳医科大学医学药房数据库确定成人丁胺卡那霉素,庆大霉素和妥布霉素的季度使用量,以1992年和2000年每1000病人日的总氨基糖苷定义的日剂量表示。从2006年至2012年。从我院的临床微生物学数据库中检索了1992年,2006年和2008年至2012年的铜绿假单胞菌,大肠杆菌和肺炎克雷伯菌的年度敏感性(不包括重复的分离株)。将季度和年度氨基糖苷使用率与其他年份进行比较。同样,还比较了同一时间范围内目标生物体对每种氨基糖苷的敏感性。结果尽管氨基糖苷的总使用量在1992年至2006年间略有下降,但在2006年至2008年间却增加了约40%,然后稳定下来。除肺炎克雷伯菌对丁胺卡那霉素的敏感性(≥17%)外,1992年至2006年间的敏感性变化均≤±9%。从1992年到2012年,磁化率的变化也均≤±9%。与铜绿假单胞菌相比,妥布霉素仍然是最活跃的(敏感度%=?90),而阿米卡星对大肠杆菌和肺炎克雷伯菌而言仍然是最活跃的(分别为98%和98%)。结论在过去的20年中,由于我们机构中氨基糖苷的使用量很少,关键的革兰氏阴性病原体的敏感性一直保持相对稳定,随着对其他​​常用抗生素的耐药性的出现,这些试剂可作为潜在的替代疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号